Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Serum proteomic profiling, by using surfaced-enhanced laser desorption/ionization-time-of-flight mass spectrometry, is one of the most promising new approaches for cancer diagnostics. Exceptional sensitivities and specificities have been reported for some cancer types such as prostate, ovarian, breast, and bladder cancers. These sensitivities/specificities are far superior to those obtained by using classical cancer biomarkers. In this review, I concentrate more on questions that cast doubt on the results reported and propose experiments to investigate these questions in detail, before the technique is used at the clinic. It is clear that the method needs to be externally and thoroughly validated before clinical implementation is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mass spectrometry-based proteomics
Aebersold, R., & Mann, M. (2003) · Nature · doi:10.1038/nature01511 · Cited by 6,955
Global analysis of protein expression in yeast
Ghaemmaghami, S., Huh, W.-K., Bower, K., Howson, R. W., Belle, A., Dephoure, N., O'Shea, E. K., & Weissman, J. S. (2003) · Nature · doi:10.1038/nature02046 · Cited by 3,750 · cited 1×
“(57) compared mass spectrometry and protein tagging methodologies combined with either Western blotting or green fluorescent protein microscopy.”
BackgroundUse of proteomic patterns in serum to identify ovarian cancer
Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07746-2 · Cited by 3,236
Tietz Textbook of Clinical Chemistry
(1999) · Archives of Pathology and Laboratory Medicine · doi:10.5858/123.7.646b · Cited by 2,495
Regulated transport of the glucose transporter GLUT4
Bryant, N. J., Govers, R., & James, D. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm782 · Cited by 1,183
Etzioni, R., Urban, N., Ramsey, S., McIntosh, M., Schwartz, S., Reid, B., Radich, J., Anderson, G., & Hartwell, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1041 · Cited by 1,155
Proteomic applications for the early detection of cancer
Wulfkuhle, J. D., Liotta, L. A., & Petricoin, E. F. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1043 · Cited by 907
Welsh, J. B., Sapinoso, L. M., Su, A. I., Kern, S. G., Wang‐Rodriguez, J., Moskaluk, C. A., Frierson, H. F., & Hampton, G. M. (2001) · PubMed · Cited by 856
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.
Hellström, I., Raycraft, J., Hayden-Ledbetter, M. S., Ledbetter, J. A., Schummer, M., McIntosh, M. W., Drescher, C. W., Urban, N. D., & Hellström, K. E. (2003) · PubMed · Cited by 813
Serum Proteomic Patterns for Detection of Prostate Cancer
Petricoin, E. F. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.20.1576 · Cited by 736
Tietz Textbook of Clinical Chemistry
David (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03520080086056 · Cited by 703
Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry
Merchant, M., & Weinberger, S. R. (2000) · Electrophoresis · doi:10.1002/(sici)1522-2683(20000401)21:6<1164::aid-elps1164>3.0.co;2-0 · Cited by 693
The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease*
Yousef, G. M., & Diamandis, E. P. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0424 · Cited by 675
Self-citationWelsh, J. B., Zarrinkar, P. P., Sapinoso, L. M., Kern, S. G., Behling, C. A., Monk, B. J., Lockhart, D. J., Burger, R. A., & Hampton, G. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1176 · Cited by 654
Use of Tandem Mass Spectrometry for Multianalyte Screening of Dried Blood Specimens from Newborns
Chace, D. H., Kalas, T. A., & Naylor, E. W. (2003) · Clinical Chemistry · doi:10.1373/clinchem.2003.022178 · Cited by 621
Baggerly, K. A., Morris, J. S., & Coombes, K. R. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg484 · Cited by 621
Adam, B.-L., Qu, Y., Davis, J. W., Ward, M. D., Clements, M. A., Cazares, L. H., Semmes, O. J., Schellhammer, P. F., Yasui, Y., Feng, Z., et al. (2002) · PubMed · Cited by 612
Clinical proteomics: translating benchside promise into bedside reality
Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C., & Liotta, L. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd891 · Cited by 550
The SELDI-TOF MS Approach to Proteomics: Protein Profiling and Biomarker Identification
Issaq, H. J., Veenstra, T. D., Conrads, T. P., & Felschow, D. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6678 · Cited by 538
Clinical proteomics: Written in blood
Liotta, L. A., Ferrari, M., & Petricoin, E. (2003) · Nature · doi:10.1038/425905a · Cited by 534
Large-Scale Delineation of Secreted Protein Biomarkers Overexpressed in Cancer Tissue and Serum
Welsh, J. B., Sapinoso, L. M., Kern, S. G., Brown, D. A., Liu, T., Bauskin, A. R., Ward, R. L., Hawkins, N. J., Quinn, D. I., Russell, P. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530278100 · Cited by 503 · cited 1×
“biomarkers will likely be secreted proteins (21); about 20–”
BackgroundOsteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer
Kim, J.-H. (2002) · JAMA · doi:10.1001/jama.287.13.1671 · Cited by 480
Qu, Y., Adam, B.-L., Yasui, Y., Ward, M. D., Cazares, L. H., Schellhammer, P. F., Feng, Z., Semmes, O. J., & Wright, G. L. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.10.1835 · Cited by 433
Diamandis, E. P. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh056 · Cited by 399
Self-citationA panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease
Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O., Corthals, G., Burkhard, P., Hochstrasser, D. F., & Sanchez, J. (2003) · PROTEOMICS · doi:10.1002/pmic.200300470 · Cited by 374
Washburn, M. P., Koller, A., Oshiro, G., Ulaszek, R. R., Plouffe, D., Deciu, C., Winzeler, E., & Yates, J. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0634629100 · Cited by 354
A data review and re-assessment of ovarian cancer serum proteomic profiling
Sorace, J. M., & Zhan, M. (2003) · BMC Bioinformatics · doi:10.1186/1471-2105-4-24 · Cited by 336
Proteomic Patterns in Biological Fluids: Do They Represent the Future of Cancer Diagnostics?
Diamandis, E. P. (2003) · Clinical Chemistry · doi:10.1373/49.8.1272 · Cited by 324
Self-citationKozak, K. R., Amneus, M. W., Pusey, S. M., Su, F., Luong, M. N., Luong, S. A., Reddy, S. T., & Farias-Eisner, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2033602100 · Cited by 276
Ye, B., Cramer, D. W., Skates, S. J., Gygi, S. P., Pratomo, V., Fu, L., Horick, N., Licklider, L., Schorge, J. O., Berkowitz, R. S., et al. (2003) · PubMed · Cited by 267
Jr, G. W., Cazares, L., Leung, S., Nasim, S., Adam, B., Yip, T., Schellhammer, P., Gong, L., & Vlahou, A. (1999) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500384 · Cited by 260
Proteomics in Early Detection of Cancer
Srinivas, P. R., Srivastava, S., Hanash, S., & Wright, G. L. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.10.1901 · Cited by 254
Human Tissue Kallikreins: A Family of New Cancer Biomarkers
Diamandis, E. P., & Yousef, G. M. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1198 · Cited by 247
Self-citationProcessing of Serum Proteins Underlies the Mass Spectral Fingerprinting of Myocardial Infarction
Marshall, J., Kupchak, P., Zhu, W., Yantha, J., Vrees, T., Furesz, S., Jacks, K., Smith, C., Kireeva, I., Zhang, R., et al. (2003) · Journal of Proteome Research · doi:10.1021/pr030003l · Cited by 229
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical chemistry
Marvin, L. F., Roberts, M. A., & Fay, L. B. (2003) · Clinica Chimica Acta · doi:10.1016/j.cccn.2003.08.008 · Cited by 226
Rogers, M. A., Clarke, P. A., Noble, J., Munro, N. P., Paul, A., Selby, P. J., & Banks, R. E. (2003) · PubMed · Cited by 220
Proteomic Approaches to Tumor Marker Discovery
Rai, A. J., Zhang, Z., Rosenzweig, J., Shih, I.-M., Pham, T., Fung, E. T., Sokoll, L. J., & Chan, D. W. (2002) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2002-126-1518-pattmd · Cited by 219
Cho, W. C. S., Yip, T. T. C., Yip, C., Yip, V., Thulasiraman, V., Ngan, R. K. C., Yip, T.-T., Lau, W.-H., Au, J. S. K., Law, S. C. K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0413-3 · Cited by 207
Characterization of Renal Allograft Rejection by Urinary Proteomic Analysis
Clarke, W., Silverman, B. C., Zhang, Z., Chan, D. W., Klein, A. S., & Molmenti, E. P. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000064293.57770.42 · Cited by 205
Tumor Markers : Physiology, Pathobiology, Technology, and Clinical Applications
Fritsche, H. A., Diamandis, E. P., & Lilja, H. G. (2002) · Cited by 197
Self-citationPeer Reviewed: SELDI-TOF MS for Diagnostic Proteomics
Issaq, H. J., Conrads, T. P., Prieto, D. A., Tirumalai, R., & D.Veenstra, T. (2003) · Analytical Chemistry · doi:10.1021/ac031249c · Cited by 188
Tumor markers. Physiology, pathobiology, technology, and clinical applications
Wu, A. H. B. (2003) · Clinica Chimica Acta · doi:10.1016/s0009-8981(03)00049-4 · Cited by 172
Diagnostic Potential of Serum Proteomic Patterns in Prostate Cancer
Bañez, L. L., Prasanna, P., Sun, L. L., Ali, A., ZOU, Z., Adam, B.-L., McLeod, D. G., Moul, J. W., & Srivastava, S. K. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000069431.95404.56 · Cited by 143
Mass spectrometry-based clinical proteomics
Pusch, W., Flocco, M. T., Leung, S.-M., Thiele, H., & Kostrzewa, M. (2003) · Pharmacogenomics · doi:10.1517/phgs.4.4.463.22753 · Cited by 134
ProteinChip clinical proteomics: computational challenges and solutions.
Fung, E. T., & Enderwick, C. (2002) · PubMed · Cited by 132
Proteomic patterns in serum and identification of ovarian cancer
Rockhill, B. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09387-x · Cited by 130
Venditti, L. N., Venditti, C. P., Berry, G. T., Kaplan, P. B., Kaye, E. M., Glick, H. A., & Stanley, C. A. (2003) · PEDIATRICS · doi:10.1542/peds.112.5.1005 · Cited by 111
A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt‐Jakob disease
Guillaume, E., Zimmermann, C., Burkhard, P. R., Hochstrasser, D. F., & Sanchez, J. (2003) · PROTEOMICS · doi:10.1002/pmic.200300478 · Cited by 82
Saugy, M., Cardis, C., Robinson, N., & Schweizer, C. (2000) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.2000.0058 · Cited by 76
The Vision for a New Diagnostic Paradigm
Petricoin, E. F., & Liotta, L. A. (2003) · Clinical Chemistry · doi:10.1373/49.8.1276 · Cited by 74
Tandem mass spectrometry in the clinical chemistry laboratory
Dooley, K. (2003) · Clinical Biochemistry · doi:10.1016/s0009-9120(03)00105-x · Cited by 73
Proteomic patterns in serum and identification of ovarian cancer
Diamandis, E. P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09390-x · Cited by 69
Self-citationPutative protein markers in the sera of men with prostatic neoplasms
Lehrer, S. P., Roboz, J., Ding, H., Zhao, S., Diamond, E. J., Holland, J., Stone, N. N., Droller, M. J., & Stock, R. G. (2003) · British Journal of Urology · doi:10.1046/j.1464-410x.2003.04341.x · Cited by 57
Serum haptoglobin in patients with ovarian malignancies.
Wk, M., Handschumacher, R. E., & Wade, M. E. (1971) · PubMed · Cited by 38
Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer
Hlavaty, J. J., Partin, A. W., Shue, M. J., Mangold, L. A., Derby, J., Javier, T., Kelley, S. W., Stieg, A. Z., Briggman, J. V., Hass, G. M., et al. (2003) · Urology · doi:10.1016/s0090-4295(03)00036-0 · Cited by 36
Finne, P., Finne, R., & Stenman, U. (2001) · British Journal of Urology · doi:10.1046/j.1464-4096.2001.02461.x · Cited by 15
Nutzung von artifiziellen neuronalen Netzwerken zur Risikoabsch�tzung eines Prostatakarzinoms
Stephan, C., Vogel, B., Cammann, H., Lein, M., Klevecka, V., Sinha, P. K., Kristiansen, G., Schnorr, D., Jung, K., & Loening, S. A. (2003) · Der Urologe · doi:10.1007/s00120-003-0322-7 · Cited by 10
Cited by
Clark, A. E., Kaleta, E. J., Arora, A., & Wolk, D. M. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00072-12 · Cited by 941
Zhang, Z., Bast, R. C., Yu, Y., Li, J., Sokoll, L. J., Rai, A. J., Rosenzweig, J. M., Cameron, B., Wang, Y. Y., Meng, X.-Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0746 · Cited by 934
Differential exoprotease activities confer tumor-specific serum peptidome patterns
Villanueva, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26022 · Cited by 741
Rai, A. J., Gelfand, C. A., Haywood, B. C., Warunek, D. J., Yi, J., Schuchard, M. D., Mehigh, R. J., Cockrill, S. L., Scott, G. B. I., Tammen, H., et al. (2005) · PROTEOMICS · doi:10.1002/pmic.200401245 · Cited by 545
Liu, T., Qian, W.-J., Gritsenko, M. A., Camp, D. G., Monroe, M. E., Moore, R. J., & Smith, R. D. (2005) · Journal of Proteome Research · doi:10.1021/pr0502065 · Cited by 405
Metadata
- Authors
- Diamandis, E. P.
- Venue
- Molecular & Cellular Proteomics
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 367-378
- ISSN
- 1535-9476 (ISSN-L)
- OpenAlex
- W2139564441
- Cited by
- 631
- References
- 57
- FWCI
- 32.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.